Literature DB >> 2994989

Enalapril maleate versus captopril. A comparison of the hormonal and antihypertensive effects.

C R Ayers, K M Baker, B A Weaver, M R Lehman.   

Abstract

24 hypertensive patients were randomised into 2 groups to compare the antihypertensive effects of enalapril and captopril over a 10-week period. In the hydrochlorothiazide run-in period, blood pressure was reduced from 171 +/- 4/109 +/- 1mm Hg to 160 +/- 4/103 +/- 1mm Hg (p less than 0.05). Angiotensin-converting enzyme (ACE) inhibition decreased blood pressure to 132 +/- 3/87 +/- 2mm Hg. Captopril decreased diastolic blood pressure significantly more after 3 hours than enalapril (-24 versus -17mm Hg, p less than 0.05). After 10 weeks of therapy, this antihypertensive response was maintained at 134 +/- 3/83 +/- 1mm Hg. There was no difference between the captopril and enalapril treated groups. Acute and chronic responses of plasma renin activity, plasma aldosterone and ACE were determined. There was an acute positive correlation between the rise in plasma renin activity and the fall in blood pressures with captopril but not with enalapril. With chronic treatment there was no difference in the ability of either of the 2 drugs to reduce blood pressure, inhibit ACE, reduce aldosterone or stimulate plasma renin activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994989     DOI: 10.2165/00003495-198500301-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

2.  Inhibition of angiotensin converting enzyme by SQ 14,225 in conscious rabbits.

Authors:  V S Murthy; T L Waldron; M E Goldberg; R R Vollmer
Journal:  Eur J Pharmacol       Date:  1977-12-01       Impact factor: 4.432

3.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

4.  The renin system: Variations in man measured by radioimmunoassay or bioassay.

Authors:  J E Sealey; J Gerten-Banes; J H Laragh
Journal:  Kidney Int       Date:  1972-04       Impact factor: 10.612

5.  An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients.

Authors:  H Gavras; H R Brunner; J H Laragh; J E Sealey; I Gavras; R A Vukovich
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

6.  Evaluation of a new commercial radioassay kit for aldosterone using an iodinated tracer.

Authors:  N P Kubasik; K Warren; H E Sine
Journal:  Clin Biochem       Date:  1979-04       Impact factor: 3.281

7.  Simple radioassay for measuring serum activity of angiotensin-converting enzyme in sarcoidosis.

Authors:  P K Rohatgi; J W Ryan
Journal:  Chest       Date:  1980-07       Impact factor: 9.410

8.  Acute and chronic effect of captropril in hypertensive patients.

Authors:  D W Johns; K M Baker; C R Ayers; E D Vaughan; R M Carey; M J Peach; M R Yancey; E M Ortt; S C Williams
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

9.  Converting enzyme inhibition with an orally active compound in hypertensive man.

Authors:  E L Bravo; R C Tarazi
Journal:  Hypertension       Date:  1979 Jan-Feb       Impact factor: 10.190

10.  Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats.

Authors:  R R Vollmer; J A Boccagno
Journal:  Eur J Pharmacol       Date:  1977-09-15       Impact factor: 4.432

View more
  2 in total

1.  Changes in indocyanine green kinetics after the administration of enalapril to healthy subjects.

Authors:  J Geneve; T Le Dinh; A Brouard; M Bails; J M Segrestaa; C Caulin
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.

Authors:  G A Christie; C Lucas; D N Bateman; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.